ml218 (Alomone Labs)


Structured Review

Ml218, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ml218/product/Alomone Labs
Average 91 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"
Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts
Journal: Journal of Pharmacology & Pharmacotherapeutics
doi: 10.4103/0976-500X.179358

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
Techniques Used:

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
Techniques Used: Standard Deviation

Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
Techniques Used: Standard Deviation
2) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"
Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts
Journal: Journal of Pharmacology & Pharmacotherapeutics
doi: 10.4103/0976-500X.179358

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
Techniques Used:

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
Techniques Used: Standard Deviation

Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
Techniques Used: Standard Deviation
3) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"
Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts
Journal: Journal of Pharmacology & Pharmacotherapeutics
doi: 10.4103/0976-500X.179358

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
Techniques Used:

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
Techniques Used: Standard Deviation

Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
Techniques Used: Standard Deviation
4) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"
Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts
Journal: Journal of Pharmacology & Pharmacotherapeutics
doi: 10.4103/0976-500X.179358

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
Techniques Used:

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
Techniques Used: Standard Deviation

Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
Techniques Used: Standard Deviation
5) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"
Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts
Journal: Journal of Pharmacology & Pharmacotherapeutics
doi: 10.4103/0976-500X.179358

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
Techniques Used:

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
Techniques Used: Standard Deviation

Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
Techniques Used: Standard Deviation
6) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"
Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts
Journal: Journal of Pharmacology & Pharmacotherapeutics
doi: 10.4103/0976-500X.179358

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
Techniques Used:

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
Techniques Used: Standard Deviation

Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
Techniques Used: Standard Deviation
7) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"
Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts
Journal: Journal of Pharmacology & Pharmacotherapeutics
doi: 10.4103/0976-500X.179358

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
Techniques Used:

Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
Techniques Used: Standard Deviation

Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
Techniques Used: Standard Deviation